The appraisal ‘Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel) [ID523]’ is currently suspended. Roche have advised that they are in ongoing discussions with NHS England to seek agreement of a commercial scheme that can be considered by NICE. All three parties (NHS England, NICE and Roche) are committed to securing the earliest possible date for the NICE committee to re-consider this appraisal. Current timelines suggest a NICE Committee meeting would be scheduled in early 2017. More information on anticipated timelines will be communicated as it becomes available.